Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful

Executive Summary

The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.

You may also be interested in...



Central IRBs, Data Security Standards Feature In Overhaul Of "Common Rule"

Clinical trials that take place at multiple U.S. sites and are covered by the "Common Rule" of federal regulations relating to human subject protection could soon be required to use a single institutional review board of record, under a proposed revision.

Central IRBs, Data Security Standards Feature In Overhaul Of "Common Rule"

Clinical trials that take place at multiple U.S. sites and are covered by the "Common Rule" of federal regulations relating to human subject protection could soon be required to use a single institutional review board of record, under a proposed revision.

Can Pfizer’s "Virtual Trial" Change The Game, Cut Development Costs?

As drug makers seek ways to reduce the cost of clinical trials, Pfizer thinks the solution could be asking patients to reach into their own pockets – for their cell phones.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel